Suppr超能文献

相似文献

1
Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.
Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):1952-9. doi: 10.1007/s00259-009-1206-x.
2
18F-FDG PET/CT evaluation of patients with ovarian carcinoma.
Nucl Med Commun. 2008 Dec;29(12):1046-51. doi: 10.1097/MNM.0b013e32831089cb.
3
18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer.
Abdom Imaging. 2015 Jan;40(1):127-33. doi: 10.1007/s00261-014-0194-x.
7
18F-FDG PET/computed tomography scan in patients with suspicion of recurrent neuroendocrine carcinoma of the cervix.
Nucl Med Commun. 2021 Oct 1;42(10):1151-1156. doi: 10.1097/MNM.0000000000001432.
8
FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
Nucl Med Commun. 2010 Jun;31(6):526-31. doi: 10.1097/MNM.0b013e32833800e7.
9
Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Nucl Med Commun. 2012 Jun;33(6):591-6. doi: 10.1097/MNM.0b013e3283516716.
10
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

引用本文的文献

1
Cancer of the cervix uteri: 2025 update.
Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1:87-108. doi: 10.1002/ijgo.70277.
2
Impact of PET/CT Imaging with FDG in Locally Advanced Cervical Carcinoma-A Literature Review.
Curr Oncol. 2024 Apr 29;31(5):2508-2526. doi: 10.3390/curroncol31050188.
3
Squamous Cell Carcinoma Antigen: Clinical Application and Research Status.
Diagnostics (Basel). 2022 Apr 24;12(5):1065. doi: 10.3390/diagnostics12051065.
4
Cancer of the cervix uteri: 2021 update.
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):28-44. doi: 10.1002/ijgo.13865.
5
Squamous cell carcinoma of uterine cervix metastatic to the axillary lymph node.
BMJ Case Rep. 2021 Jul 12;14(7):e243989. doi: 10.1136/bcr-2021-243989.
6
Implications of the new FIGO staging and the role of imaging in cervical cancer.
Br J Radiol. 2021 Sep 1;94(1125):20201342. doi: 10.1259/bjr.20201342. Epub 2021 May 14.
7
Diagnostic Strategies for Recurrent Cervical Cancer: A Cohort Study.
Front Oncol. 2020 Dec 7;10:591253. doi: 10.3389/fonc.2020.591253. eCollection 2020.
9
Role of MRI in staging and follow-up of endometrial and cervical cancer: pitfalls and mimickers.
Insights Imaging. 2019 Feb 13;10(1):19. doi: 10.1186/s13244-019-0696-8.

本文引用的文献

1
Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.
Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):362-72. doi: 10.1007/s00259-008-0956-1. Epub 2008 Oct 18.
2
New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET.
Cancer Treat Rev. 2008 Dec;34(8):671-81. doi: 10.1016/j.ctrv.2008.08.003. Epub 2008 Oct 11.
3
Role of PET/CT in the evaluation of cervical cancer.
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S55-9. doi: 10.1016/j.ygyno.2008.05.023. Epub 2008 Jul 29.
4
Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer.
Eur Radiol. 2008 Oct;18(10):2040-7. doi: 10.1007/s00330-008-0979-9. Epub 2008 Apr 19.
7
PET/CT and cross sectional imaging of gynecologic malignancy.
Cancer Imaging. 2007 Oct 1;7 Spec No A(Special issue A):S130-8. doi: 10.1102/1470-7330.2007.9015.
9
The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study.
Gynecol Oncol. 2007 Jul;106(1):29-34. doi: 10.1016/j.ygyno.2007.03.027. Epub 2007 May 7.
10
Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.
Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):472-9. doi: 10.1007/s00259-006-0251-y. Epub 2006 Nov 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验